In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.95 above Elutia Inc average.

Within Biotechnology & Pharmaceuticals industry 115 other companies have achieved higher Quick Ratio than Elutia Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 1637, from total ranking in the first quarter 2026 at 1835.

Explain Quick Ratio?
How much Cash & cash equivalents ELUT�s has?
What are ELUT�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ELUT Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	-37.27 %	-41.87 %	-37.9 %	1.58 %	-3.07 %
Y / Y Cash & cash equivalent Change	134.07 %	64.12 %	174.57 %	-81.66 %	-53.27 %
Quick Ratio MRQ	0.95	1.56	1.75	0.13	0.25
ELUT's Total Ranking	# 1637	# 1835	# 4335	# 3860	# 3032
Seq. Current Liabilities Change	15.47 %	-12.12 %	-42.12 %	6.81 %	7.01 %
Seq. Cash & cash equivalent Change	-30.16 %	-21.63 %	669.96 %	-44.46 %	-51.03 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 116
Healthcare Sector	# 639
Overall Market	# 2020

Quick Ratio Statistics
High	Average	Low
1.75	0.71	0.06
(Dec 31 2025)		(Sep 30 2020)

Financial Statements
Elutia Inc 's Current Liabilities	$ 21 Millions	Visit ELUT's Balance sheet
Elutia Inc 's Cash & cash equivalent	$ 20 Millions	Visit ELUT's Balance sheet
Source of ELUT's Sales		Visit ELUT's Sales by Geography

Cumulative Elutia Inc 's Quick Ratio

ELUT's Quick Ratio for the trailling 12 Months

ELUT Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-28.25 %	-19.53 %	-9.72 %	1.27 %	2.64 %
Y / Y Cash & cash equivalent TTM Growth	37.97 %	4.74 %	-4 %	-42.16 %	0.47 %
Quick Ratio TTM	0.93	0.72	0.55	0.33	0.49
Total Ranking TTM	# 4042	# 2772	# 3005	# 3066	# 2890
Seq. Current Liabilities TTM Growth	-11.54 %	-10.81 %	-9.44 %	0.42 %	-0.79 %
Seq. Cash & cash equivalent TTM Growth	14.6 %	16.63 %	52.74 %	-32.42 %	-13 %

Quick ratio ranking by company, industry and sector >> Back to ELUT Financial Strength Comparisons >> Go to Compare ELUT Quick Ratio to its Competitors

News about Elutia Inc Quick Ratio

Elutia Inc. Captures Investor Confidence with $13.26 Million Registered Direct Offering for Future Growth

Elutia Inc. Raises Funds through Registered Direct Offering to Fuel Growth
Silver Spring-based company, Elutia Inc., recently announced a registered direct offering that is set to raise approximately $13.26 million for the company. The offering entails the purchase and sale of 3,175,000 shares of Elutia s Class A common stock, priced at $3.40 per share, along with 725,000 prefunded warrants at a purchase price of $3.399 per warrant. The prefunded warrants are exercisable immediately at an exercise price of $0.001 per warrant. Elutia aims to utilize the proceeds to fund various growth initiatives. The offering is anticipated to conclude by June 18, 2024, pending customary closing conditions.
Elutia Inc., a Nasdaq listed company (symbol: ELUT), has secured a definitive agreement with investors for the registered direct offering, signifying a significant milestone for the organization. The offering involves the sale of a considerable number of shares and warrants, presenting a lucrative opportunity for investors to support Elutia s strategic objectives. The purchase price for each share and prefunded warrant reflects the company s market value and the confidence of investors in its future prospects.

On the trailing twelve months basis ELUT Cash & cash equivalent more than doubled by 134.07 % in Q2 2026 year on year, while Current Liabilities increased to $21 millions, this led to increase in in Elutia Inc 's Quick Ratio to 0.93, above ELUT average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 143 other companies have achieved higher Quick Ratio than Elutia Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2772 to 4042.

Explain Quick Ratio?
How much Cash & cash equivalents ELUT�s has?
What are ELUT�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 144
Healthcare Sector	# 905
Within the Market	# 4042

trailing twelve months Quick Ratio Statistics
High	Average	Low
1.23	0.58	0.28
(Sep 30 2021)		(Jun 30 2023)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Sana Biotechnology Inc	2.59	$ 320.990 Millions	$ 123.752 Millions
Tarsus Pharmaceuticals Inc	2.56	$ 449.690 Millions	$ 175.753 Millions
Meiragtx Holdings Plc	2.46	$ 143.166 Millions	$ 58.096 Millions
Kodiak Sciences Inc	2.39	$ 125.903 Millions	$ 52.770 Millions
Exelixis Inc	2.32	$ 839.385 Millions	$ 361.927 Millions
Precision Biosciences Inc	2.19	$ 87.549 Millions	$ 39.886 Millions
Novavax inc	2.18	$ 719.340 Millions	$ 330.574 Millions
Regenxbio Inc	2.11	$ 174.530 Millions	$ 82.621 Millions
Biocardia Inc	2.00	$ 4.117 Millions	$ 2.055 Millions
Kymera Therapeutics Inc	1.75	$ 124.477 Millions	$ 71.326 Millions
Biocryst Pharmaceuticals Inc	1.69	$ 353.279 Millions	$ 208.846 Millions
Coherus Oncology inc	1.69	$ 127.683 Millions	$ 75.510 Millions
Bio techne Corp	1.62	$ 264.712 Millions	$ 163.700 Millions
Atara Biotherapeutics Inc	1.45	$ 9.900 Millions	$ 6.847 Millions
Twist Bioscience Corporation	1.39	$ 166.839 Millions	$ 120.255 Millions
Neumora Therapeutics Inc	1.34	$ 116.834 Millions	$ 87.478 Millions
Calidi Biotherapeutics Inc	1.33	$ 4.290 Millions	$ 3.237 Millions
Passage Bio Inc	1.17	$ 24.155 Millions	$ 20.719 Millions
Mink Therapeutics Inc	1.16	$ 8.807 Millions	$ 7.569 Millions
Amgen Inc	1.07	$ 27,404.000 Millions	$ 25,502.000 Millions
Aligos Therapeutics Inc	1.07	$ 30.381 Millions	$ 28.343 Millions
Vaxart Inc	1.05	$ 77.058 Millions	$ 73.108 Millions
Iovance Biotherapeutics inc	1.04	$ 110.768 Millions	$ 106.848 Millions
Liminatus Pharma Inc	0.99	$ 3.017 Millions	$ 3.040 Millions
Elutia Inc	0.95	$ 19.896 Millions	$ 21.045 Millions
Jasper Therapeutics Inc	0.93	$ 7.314 Millions	$ 7.845 Millions
Protalix Biotherapeutics inc	0.90	$ 28.140 Millions	$ 31.391 Millions
Vivosim Labs Inc	0.88	$ 1.670 Millions	$ 1.893 Millions
Senti Biosciences Holdings Inc	0.83	$ 13.124 Millions	$ 15.765 Millions
Pelthos Therapeutics Inc	0.78	$ 24.776 Millions	$ 31.959 Millions

Date modified: 2026-09-08T17:33:17+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.